Legal Cannabis Saved Medicare $165 Million Per Year by Reducing Prescriptions
Medical Marijuana Laws Reduce Prescription Medication Use In Medicare Part D.
In states with medical cannabis laws, Medicare prescriptions for pain, nausea, anxiety, depression, seizures, and sleep dropped significantly — saving $165.2 million per year and demonstrating population-level drug substitution.
Bachhuber showed that states with medical cannabis laws had fewer opioid deaths. But deaths are a lagging indicator — the endpoint of a long chain of prescribing, dependence, dose escalation, and overdose. Ashley and David Bradford asked a simpler, earlier question: when states legalize medical cannabis, do doctors write fewer prescriptions?
They looked at the place where prescribing is most precisely tracked: Medicare Part D, the federal prescription drug benefit covering tens of millions of Americans. And they found something the pharmaceutical industry didn't want to see: in every drug category for which cannabis could serve as an alternative, prescriptions dropped — and the savings were measured in hundreds of millions of dollars.
The Analysis
The Bradfords analyzed Medicare Part D prescribing data from 2010 to 2013, comparing states that had implemented medical cannabis laws to those that hadn't. They focused specifically on drug categories where cannabis has a plausible therapeutic alternative: pain, nausea, anxiety, depression, psychosis, seizures, sleep disorders, and spasticity.
The reductions weren't limited to opioids. In states with medical cannabis laws, prescriptions decreased for:
- Pain medications (including opioids) — the largest reduction
- Anti-nausea medications — consistent with cannabis's well-documented antiemetic properties
- Anti-anxiety medications — suggesting patients may be substituting cannabis for benzodiazepines
- Antidepressants — a more surprising finding
- Anti-seizure medications — consistent with the CBD-epilepsy evidence
- Sleep medications — consistent with cannabis's sedative properties
Why This Study Matters More Than The Numbers Suggest
The Bradfords' analysis was important not just for the dollar figures, but for what it revealed about how medicine is practiced. When patients have access to cannabis, they and their doctors make different choices. The prescribing changes weren't random — they tracked exactly the conditions where cannabis has therapeutic plausibility. This is biologially coherent substitution, not noise.
The study also had a clever natural experiment built in: states with active dispensaries (where cannabis was actually accessible) showed larger prescribing reductions than states with laws but no dispensaries. This dose-response relationship — more access, more substitution — strengthens the causal argument.
The Follow-Up
The Bradfords published a companion study (2017) using the same approach with Medicaid data and found similar results: states with medical cannabis laws showed significant reductions in Medicaid prescriptions for pain, depression, nausea, anxiety, and seizures. A subsequent study (2018) examining Medicare Part D specifically for opioids found that states with medical cannabis laws had 2.21 million fewer daily opioid doses prescribed per year.
These replications across different datasets, insurance programs, and time periods strengthened the original finding considerably.
Myth vs. Reality
Cannabis legalization just adds another drug to the mix — it doesn't reduce other drug use.
Multiple analyses of actual prescribing data show that legal cannabis access is associated with measurable reductions in prescriptions for opioids, anti-anxiety medications, antidepressants, sleep aids, anti-nausea drugs, and seizure medications. Patients are substituting, not just adding.
The Evidence
Bradford & Bradford (2016) found $165.2M in annual Medicare savings. Subsequent analyses of Medicaid, Medicare Part D, and commercial insurance showed similar patterns. States with dispensaries showed larger effects than states with laws but no access points.
Bradford & Bradford (2016, 2017, 2018)
The Limitations
This study shares the ecological design limitations of Bachhuber's work — it compares states, not individuals. The reductions could reflect other policy changes that correlate with cannabis legalization. And the study can't determine whether the prescribing reductions improved or worsened patient outcomes. Fewer opioid prescriptions is probably good; fewer antidepressant prescriptions is less clearly positive, since trading SSRIs for cannabis requires careful consideration.
The $165.2 million figure sounds large but represents a small fraction of total Medicare Part D spending (~$100 billion per year). The clinical significance for individual patients may be more meaningful than the aggregate economic impact.
Frequently Asked Questions
Cite this study
Bradford, Ashley C; Bradford, W David. (2016). Medical Marijuana Laws Reduce Prescription Medication Use In Medicare Part D.. Health Affairs, 35(7), 1230-1236. https://doi.org/10.1377/hlthaff.2015.1661